Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

Trial Profile

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2018

At a glance

  • Drugs Defactinib (Primary) ; Carboplatin; Paclitaxel
  • Indications Adenocarcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ROCKIF Trial
  • Most Recent Events

    • 10 Oct 2018 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
    • 10 Oct 2018 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2023.
    • 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top